1. Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients
   Bibhu Ranjan Das et al, 2015, Pathology & Oncology Research CrossRef
2. Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
   Cong Wang et al, 2018, Frontiers in Pharmacology CrossRef
3. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model
   Bhaswati Sarcar et al, 2019, FEBS Open Bio CrossRef
4. Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
   Nijia Chang et al, 2020, Oncology Letters CrossRef
5. Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
   Martin Faehling et al, 2017, Oncotarget CrossRef
6. Germline EGFR mutations in lung cancer (Review)
   Minghui Liu et al, 2023, Oncology Letters CrossRef
7. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review
   James Sherwood et al, 2015, Journal of Experimental & Clinical Cancer Research CrossRef
8. Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC
   Linhong He et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
9. Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC
   Sabrina Rossi et al, 2022, Current Problems in Cancer CrossRef
10. Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
    Idris Bahce et al, 2016, EJNMMI Research CrossRef
11. Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
    T. C. Schneider et al, 2015, International Journal of Endocrinology CrossRef
12. Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS
    Katja Tuononen et al, 2013, Genes, Chromosomes and Cancer CrossRef
13. High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event
    Katinka Rüping et al, 2014, Journal of Cancer Research and Clinical Oncology CrossRef
14. EGFR L858R Mutation May Go Undetected Because of P848L in cis Mutation
    Iñigo Santamaría et al, 2013, Journal of Clinical Oncology CrossRef
15. Optimization of PCR Conditions for Amplification of GC-RichEGFRPromoter Sequence
    Jasmina Obradovic et al, 2013, Journal of Clinical Laboratory Analysis CrossRef
16. Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
    Xinqing Lin et al, 2021, Frontiers in Oncology CrossRef